Cargando…
Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections
PURPOSE: To analyze the use of artificial tears in patients undergoing treatment with anti-vascular endothelial growth (anti-VEGF) intravitreal injections. METHODS: Thirty-four eyes undergoing anti-VEGF treatment were analyzed. Each patient underwent a subjective and objective evaluation of the ocul...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719699/ https://www.ncbi.nlm.nih.gov/pubmed/36474999 http://dx.doi.org/10.2147/OPTH.S391082 |
_version_ | 1784843383521411072 |
---|---|
author | Pastor-Pascual, Francisco Pastor-Pascual, Rafael Gálvez-Perez, Patricia Dolz-Marco, Rosa Gallego-Pinazo, Roberto |
author_facet | Pastor-Pascual, Francisco Pastor-Pascual, Rafael Gálvez-Perez, Patricia Dolz-Marco, Rosa Gallego-Pinazo, Roberto |
author_sort | Pastor-Pascual, Francisco |
collection | PubMed |
description | PURPOSE: To analyze the use of artificial tears in patients undergoing treatment with anti-vascular endothelial growth (anti-VEGF) intravitreal injections. METHODS: Thirty-four eyes undergoing anti-VEGF treatment were analyzed. Each patient underwent a subjective and objective evaluation of the ocular surface, using the Ocular Surface Disease Index (OSDI), Dry Eye Questionnaire (DEQ)-5, tear meniscus height (TMH), first and average non-invasive Keratograph Break-Up Time (NIKBUT), bulbar conjunctival redness, meibography and the Vision Break-Up Time (VBUT). Patients attended 5 visits (days 0, 7, 30, 37, and 60). All patients continued with their intravitreal injection treatment during the study (days 0, 30, and 60). Patients did not receive any artificial tear treatment during the first month of the study, and at the baseline visit they were randomly assigned to one of two study groups to receive either the Systane Hydration or the Viscofresh 10mg/mL formulation. Patients were instructed to instill one drop of the assigned study treatment 3 times a day for 30 days during the second month of the study. RESULTS: According to the Mixed Models for Repeated Measures analysis, there is not enough statistical evidence for any of the parameters examined to determine significant differences between being treated with artificial tears and not being treated (p > 0.05). There is, however, a tendency toward improved outcomes in some parameters when artificial tears were used. OSDI, DEQ-5, TMH, and meibography were not affected by either the type of artificial tear used or by the time (from day 30 to day 60; p > 0.05), but the NIKBUT and VBUT values increased over time during this period regardless of which treatment the patient was receiving. CONCLUSION: The use of artificial tears may help to keep the tear film stable Future studies with larger samples should be conducted to elucidate whether the tendency reported in our study becomes significant. |
format | Online Article Text |
id | pubmed-9719699 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-97196992022-12-05 Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections Pastor-Pascual, Francisco Pastor-Pascual, Rafael Gálvez-Perez, Patricia Dolz-Marco, Rosa Gallego-Pinazo, Roberto Clin Ophthalmol Clinical Trial Report PURPOSE: To analyze the use of artificial tears in patients undergoing treatment with anti-vascular endothelial growth (anti-VEGF) intravitreal injections. METHODS: Thirty-four eyes undergoing anti-VEGF treatment were analyzed. Each patient underwent a subjective and objective evaluation of the ocular surface, using the Ocular Surface Disease Index (OSDI), Dry Eye Questionnaire (DEQ)-5, tear meniscus height (TMH), first and average non-invasive Keratograph Break-Up Time (NIKBUT), bulbar conjunctival redness, meibography and the Vision Break-Up Time (VBUT). Patients attended 5 visits (days 0, 7, 30, 37, and 60). All patients continued with their intravitreal injection treatment during the study (days 0, 30, and 60). Patients did not receive any artificial tear treatment during the first month of the study, and at the baseline visit they were randomly assigned to one of two study groups to receive either the Systane Hydration or the Viscofresh 10mg/mL formulation. Patients were instructed to instill one drop of the assigned study treatment 3 times a day for 30 days during the second month of the study. RESULTS: According to the Mixed Models for Repeated Measures analysis, there is not enough statistical evidence for any of the parameters examined to determine significant differences between being treated with artificial tears and not being treated (p > 0.05). There is, however, a tendency toward improved outcomes in some parameters when artificial tears were used. OSDI, DEQ-5, TMH, and meibography were not affected by either the type of artificial tear used or by the time (from day 30 to day 60; p > 0.05), but the NIKBUT and VBUT values increased over time during this period regardless of which treatment the patient was receiving. CONCLUSION: The use of artificial tears may help to keep the tear film stable Future studies with larger samples should be conducted to elucidate whether the tendency reported in our study becomes significant. Dove 2022-11-30 /pmc/articles/PMC9719699/ /pubmed/36474999 http://dx.doi.org/10.2147/OPTH.S391082 Text en © 2022 Pastor-Pascual et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Clinical Trial Report Pastor-Pascual, Francisco Pastor-Pascual, Rafael Gálvez-Perez, Patricia Dolz-Marco, Rosa Gallego-Pinazo, Roberto Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections |
title | Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections |
title_full | Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections |
title_fullStr | Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections |
title_full_unstemmed | Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections |
title_short | Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections |
title_sort | use of artificial tears in patients undergoing treatment with anti-vegf intravitreal injections |
topic | Clinical Trial Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719699/ https://www.ncbi.nlm.nih.gov/pubmed/36474999 http://dx.doi.org/10.2147/OPTH.S391082 |
work_keys_str_mv | AT pastorpascualfrancisco useofartificialtearsinpatientsundergoingtreatmentwithantivegfintravitrealinjections AT pastorpascualrafael useofartificialtearsinpatientsundergoingtreatmentwithantivegfintravitrealinjections AT galvezperezpatricia useofartificialtearsinpatientsundergoingtreatmentwithantivegfintravitrealinjections AT dolzmarcorosa useofartificialtearsinpatientsundergoingtreatmentwithantivegfintravitrealinjections AT gallegopinazoroberto useofartificialtearsinpatientsundergoingtreatmentwithantivegfintravitrealinjections |